Medical Angels, a prominent doctor-led investor syndicate, has officially launched its inaugural venture capital fund with a target of AUD $40 million. The new entity, Medical Angels Venture Fund I, aims to leverage the clinical expertise of its extensive medical network to support Australian healthtech startups. With serial founder Michal Batko joining as a venture partner, the fund has already secured $4 million in commitments.
From Syndicate to Formal Fund
For nine years, Medical Angels has operated as a successful syndicate, channeling $18 million into over 30 promising health startups. This impressive portfolio, which boasts a 100% survival rate, was built on the collective wisdom of medical professionals. The strategic decision to formalize into an Early Stage Venture Capital Limited Partnership (ESVCLP) fund signals a new phase of growth.
The organization was co-founded by Dr. Mian Bi, an emergency clinician, and Dr. Amandeep Hansra, a GP and former deep tech fund principal. Their combined experience identified a critical need for investment decisions grounded in genuine clinical understanding. This new fund structure allows them to scale their impact and offer more substantial support to early-stage companies.
Bolstering Operations with Venture Expertise
The appointment of Michal Batko as a part-time venture partner is a key element of the fund's new strategy. Batko, the founder of Hourglass AI and former head of Startmate, brings extensive operational and venture capital experience to the team. He will focus on building the fund's infrastructure, managing investor relations, and overseeing the capital raise.
Batko describes his role as building the "engine" around the doctors' unparalleled clinical insight, enabling the fund to "punch well above its weight." While his primary focus remains Hourglass AI, he was compelled by the fund's powerful thesis. His operator muscle is intended to complement the medical team's judgment, which he notes "you can't fake."
A Unique Investment Thesis
Medical Angels operates on the conviction that the most valuable advantage in healthtech venture is clinical judgment at scale. The fund addresses a common friction point for founders: pitching to generalist investors who cannot adequately evaluate clinical data or regulatory pathways. This new fund provides not just capital, but access to a network that can validate technology and open doors.
The core philosophy was best summarized by Batko as "the money follows the medicine," a line that convinced him to join the team. This principle highlights the fund's unique alignment, where investors are the doctors who may prescribe or use the innovations they back. This creates a powerful feedback loop and a level of due diligence embedded in real-world medical practice.
A Portfolio of Proven Impact
The success of this doctor-led approach is evident in its existing portfolio companies making tangible differences in patient care. Smileyscope, a VR-based therapeutic for reducing pain and anxiety in children, has been used in over 400,000 procedures globally. This demonstrates the potential for technologies vetted by clinicians to achieve widespread adoption.
Other notable investments include Coviu, the telehealth platform that now facilitates 300,000 consultations monthly. Additionally, Clean Slate Clinic is delivering the country's first fully-virtual alcohol detox program, having already treated over 3,000 patients. These companies exemplify the fund's focus on scalable solutions to pressing healthcare challenges.
The launch of Medical Angels Venture Fund I marks a significant maturation of specialist, doctor-led investing in Australia's healthtech sector. By combining deep clinical expertise with seasoned operational leadership, the $40 million fund is uniquely positioned to scale transformative medical innovations. This model not only de-risks investments but also accelerates the path from concept to clinical practice, promising a healthier future.